Clinical Trial Update: A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating different regimens of aflibercept 8 mg in Chinese patients with polypoidal choroidal vasculopathy, assessing efficacy, durabil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD) | Phase 4 | Status: NOT_YET_RECRUITING